← Argenx
Episodes featuring Argenx
13 episodes, newest first.
- Nov 10, 2026
Midterms Put FDA Leadership and Drug Pricing in PlayBioCentury This WeekNov 10, 2026 - Nov 6, 2026
Election stakes meet biotech’s regulatory and pipeline risksBiotech HangoutNov 6, 2026 - Oct 20, 2026
China reshapes biotech deals as RNAi reaches the brainBioCentury This WeekOct 20, 2026 - Oct 16, 2026
Biotech selloff tests valuations as clinical bets advanceBiotech HangoutOct 16, 2026 - Oct 13, 2026
Biotech markets cool as trial failures test the sectorBioCentury This WeekOct 13, 2026 - Aug 17, 2026
Drug setbacks and copper demand reshape European stock movesStock MoversAug 17, 2026 - Aug 17, 2026
Mining gains meet drug-trial surprises across European marketsStock MoversAug 17, 2026 - Aug 17, 2026
European miners rise as drug trials reshape pharma stocksStock MoversAug 17, 2026 - Aug 17, 2026
European shares split across drugs, copper and biotechStock MoversAug 17, 2026 - Jul 27, 2026
Argenx buys Forte Biosciences for billions as media merger talks stallStock MoversJul 27, 2026 - Jul 27, 2026
Nvidia considers massive OpenAI backstop while biotech and telecom sectors surgeStock MoversJul 27, 2026 - Jun 30, 2026
LeBron’s Lakers exit reshapes both sides’ next moveThe Herd with Colin CowherdJun 30, 2026 - Jun 30, 2026
LeBron’s exit forces Lakers to rethink their next moveThe Herd with Colin CowherdJun 30, 2026